Table 1.
Association of cMK2 expression and nETV1 expression with clinicopathologic parameters in patients with esophageal cancer.
| Factors | All (n=323) | cMK2 (n=314) | nETV1 (n=323) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (%) | high | (%) | low/absent | (%) | p-value | high | (%) | low/absent | (%) | p-value | |||||
| Age (SD) | 65.8 | (10.6) | 65.3 (10.6) | 66.0 (10.8) | >0.05 | 63.7 (11.1) | 66.0 (10.6) | >0.05 | |||||||
| Sex | >0.05 | >0.05 | |||||||||||||
| Male | 248 | (76.8) | 115 | (36.6) | 126 | (40.1) | 16 | (5.0) | 232 | (71.8) | |||||
| Female | 75 | (23.2) | 27 | (8.6) | 46 | (14.6) | 4 | (1.2) | 71 | (22.0) | |||||
| Tumor Type | <0.001 | >0.05 | |||||||||||||
| AC | 192 | (59.4) | 104 | (33.1) | 83 | (26.4) | 11 | (3.4) | 181 | (56.0) | |||||
| SCC | 131 | (40.6) | 38 | (12.1) | 89 | (28.3) | 9 | (2.8) | 122 | (37.8) | |||||
| (y)pT | 0.009 | <0.001 | |||||||||||||
| 1 | 58 | (17.9) | 32 | (10.2) | 21 | (6.7) | 13 | (4.0) | 45 | (13.9) | |||||
| 2 | 80 | (24.8) | 24 | (7.6) | 54 | (17.2) | 2 | (0.6) | 78 | (24.1) | |||||
| 3 | 170 | (52.6) | 80 | (25.5) | 88 | (28.0) | 5 | (1.5) | 165 | (51.1) | |||||
| 4 | 15 | (4.7) | 6 | (1.9) | 9 | (2.9) | 0 | (0.0) | 15 | (4.6) | |||||
| (y)pN | 0.009 | 0.002 | |||||||||||||
| 0 | 111 | (34.4) | 38 | (12.1) | 66 | (21.0) | 14 | (4.3) | 97 | (30.0) | |||||
| 1 | 91 | (28.2) | 38 | (12.1) | 52 | (16.6) | 6 | (1.9) | 85 | (26.3) | |||||
| 2 | 61 | (18.9) | 28 | (8.9) | 32 | (10.2) | 0 | (0.0) | 61 | (18.9) | |||||
| 3 | 60 | (18.5) | 38 | (12.1) | 22 | (7.0) | 0 | (0.0) | 60 | (18.6) | |||||
| (y)G | 0.04 | 0.01 | |||||||||||||
| 1 | 18 | (5.6) | 6 | (1.9) | 11 | (3.5) | 4 | (1.2) | 14 | (4.3) | |||||
| 2 | 175 | (54.2) | 67 | (21.3) | 101 | (32.2) | 11 | (3.4) | 164 | (50.8) | |||||
| 3 | 130 | (40.2) | 69 | (21.9) | 60 | (19.1) | 5 | (1.5) | 125 | (38.7) | |||||
| R | >0.05 | >0.05 | |||||||||||||
| 0 | 282 | (87.3) | 127 | (40.4) | 148 | (47.1) | 18 | (5.6) | 264 | (81.7) | |||||
| 1 | 41 | (12.7) | 15 | (4.8) | 24 | (7.6) | 2 | (0.6) | 39 | (12.1) | |||||
| UICC Staging | 0.02 | <0.001 | |||||||||||||
| I | 73 | (22.6) | 26 | (8.3) | 41 | (13.1) | 12 | (3.7) | 61 | (18.9) | |||||
| II | 71 | (21.9) | 28 | (8.9) | 42 | (13.4) | 5 | (1.5) | 66 | (20.4) | |||||
| III | 179 | (55.5) | 88 | (28.0) | 89 | (28.3) | 3 | (0.9) | 176 | (54.5) | |||||
| NT | 0.04 | >0.05 | |||||||||||||
| yes | 73 | (22.6) | 40 | (12.7) | 31 | (9.9) | 5 | (1.5) | 68 | (21.1) | |||||
| no | 250 | (77.4) | 102 | (32.5) | 141 | (44.9) | 15 | (4.6) | 235 | (72.8) | |||||
| Adjuvant Treatment | >0.05 | 0.03 | |||||||||||||
| yes | 156 | (48.3) | 73 | (23.2) | 80 | (25.5) | 5 | (1.5) | 151 | (46.7) | |||||
| no | 167 | (51.7) | 69 | (22.0) | 92 | (29.3) | 15 | (4.6) | 152 | (47.1) | |||||
cMK2 = cytoplasmic (MAPK)-activated protein kinase 2; nETV1 nuclear of Ets variant gene 1; SD = standard deviation; AC = adenocarcinomas; SCC = squamous cell carcinomas; R = resection margin; UICC = Union for International Cancer Control; NT = neoadjuvant therapy; AT = adjuvant therapy